Technical R&D and Demonstration of Intelligent Medical Care in Alzheimer's Disease's Management

• Status: Recruiting
• Trial end date: 2025-12-09
• Target enrollment: 0
• Participant gender: All

Summary

This is a study on patient registry, and the sample size of this clinicaltrial is designed in group sequential design. According to the diagnostic criteria, the subjects are divided into SCD group, MCI group and mild dementia group. At the early stage of treatment, the doctors give patients transcutaneous electrical acupoint stimulation and music therapy according to the guidance of TCM syndrome differentiation. Patients can treat themselves at home after doctors give them intelligent device and music，and according to the TCM syndrome score, neuropsychological scale, curative effect evaluation of daily life ability scale, determining the optimal comprehensive treatment plan,and phase in the treatment of patients with food, clothing, shelter, line, and life aspects of health education and guidance, a total of 24 weeks of treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Shaanxi Hospital of Traditional Chinese Medicine
• Treatments: Donepezil

Criteria

Inclusion Criteria:

• Patients who meet the diagnostic criteria of SCD, MCI and mild dementia;

• Memory decline (self-reported or confirmed by both informants);

• Age 55-75 years;

• Memory impairment has not reached the diagnostic criteria of moderate and severe dementia;

• Hachinski ischemia scale score ≤ 4;

• Exclude any other systemic diseases that can cause brain dysfunction;

• Hamilton Depression Scale < 17;

• The subject or guardian signed the informed consent.

Exclusion Criteria:

• There are advanced, serious or unstable other diseases, such as liver, kidney and other serious primary diseases;

• severe hearing and visual impairment, can not cooperate with the assessment;

• patients with active epilepsy;

• Previous history of mental illness;

• Moderate or severe dementia, cerebral infarction or any physical or mental disorder that may lead to brain dysfunction;

• Patients who had used other drugs that may cause cognitive function changes or heart, brain, kidney and other important organs failure before inclusion;

• patients under 55 years old or above 75 years old;

• unable to cooperate with the completion of the corresponding assessment and inspection and quit;

• those who are likely to have poor compliance with the test;

• Participants in other subjects.